Health & Medicine - Posted by Jocelyn Duffy-Carnegie Mellon on Monday, October 17, 2011 12:19 - 0 Comments
Live view of neural stem cells with MRI
CARNEGIE MELLON (US) — An MRI-based technique that allows researchers to non-invasively follow stem cells in vivo could be used to develop treatments for brain injury caused by trauma, stroke, Parkinson’s disease, and other neurological disorders.
Neural stem cells are born deep in an area of the brain called the subventricular zone. As time goes on, the cells, also called neuroblasts, make their way to other areas of the brain where they mature into functioning neurons. The brain’s ability to regenerate its cells is of great interest to scientists.
“If we could better understand the molecular migratory signals that guide neuroblasts, we could try to redirect these cells to areas of the brain harmed by stroke or traumatic brain injury,” says Eric Ahrens, associate professor of biological sciences at Carnegie Mellon University. “With this information, scientists might be able to one day repair the brain.”
MRI images of neuronal stem cells tagged with a ferritin-based reporter. (Credit: Carnegie Mellon University)
Straight from the Source
Studying cells in a living brain is problematic. Common forms of in vivo cell imaging like fluorescence and bioluminescence rely on light to produce images, making them unsuitable for viewing neuroblasts buried deep beneath the skull and layers of opaque tissue. Until now, scientists had only been able to study neuronal stem cells by looking at slices of the brain under a microscope. Ahrens was able to surmount this problem using MRI technology.
Rather than light, MRI uses magnets to create high-resolution images. A typical MRI scan uses a magnetic field and radio frequency pulses to cause the hydrogen protons found in the body’s water molecules to give off signals. Those signals are converted into a high-resolution image.
At the foundation of this work is technology Ahrens developed in 2005 that causes cells to produce their own contrast agent allowing them to be imaged with MRI. Using a viral vector, Ahrens incorporated the gene that produces the naturally occurring metalloprotein ferritin into living cells.
Ferritin, which is present in all biological cells, harvests and stores naturally occurring iron. When the cells tagged with ferritin began to produce increased amounts of the protein, they draw in additional iron, turning themselves into nanomagnets.
This disrupts the magnetic field surrounding the tagged cells, changing the signal given off by adjacent water molecules. This change appears as dark spots on the MRI image indicating the cells’ presence. Since then, Ahrens’ team has improved on the process, developing an engineered form of ferritin that is a more effective MRI reporter than naturally occurring ferritin.
In the current study, published online in the journal NeuroImage, Ahrens and biological sciences postdoctoral student Bistra Iordanova used the same technique as in the initial study, this time tagging neuroblasts with the engineered ferritin. The DNA sequence for the engineered metalloprotein was incorporated into an adenovirus vector, which was then injected into the subventricular zone of a rat brain.
The adenovirus infected the neural stem cells giving the cells the genetic instructions to begin producing the ferritin reporter. Iordanova then imaged the brain with MRI and found that she was able to follow—in real time—the neuroblasts as they traveled toward the olfactory bulb and ultimately formed new inhibitory neurons.
These results mirrored what had been observed in histology studies.
Carnegie Mellon has received a patent for the reporter and Ahrens hopes to continue to develop the technology in order to allow researchers to better understand neuronal stem cells and how neurons regenerate.
Ahrens also plans to use the reporters to improve clinical trials of cell-based therapies. By incorporating the reporter into the cells before implantation, researchers would be able to find the answer to a number of critical questions, he says.
“Where do these cells go, days, weeks, and months later? How do we know that they’ve grafted to the right cells? Or have they grafted in the wrong place? Or died?” “The reporter can show us the answers.”
More news from Carnegie Mellon University: www.cmu.edu/news/